


Certificate of Express Mailing

Express Mail Label No.: EV 584173973 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 and is addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.



By Barbara Bryant
Barbara Bryant

Date: May 6, 2005

PATENT

Attorney Docket No. P-144-US2

Customer No. 27038

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	Confirmation Number: 4781
)	
John H. GRIFFIN et al.)	Group Art Unit: 1626
)	
Application No.: 10/691,094)	Examiner: Janet L. Coppins
)	
Filed: October 22, 2003)	
)	
For: INDOLINONE DERIVATIVES)	
)	
)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

05/10/2005 EHA7LE1 00000041 500344 10691094
01 FC:1606 180.00 DA

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants respectfully submit this Information Disclosure Statement (IDS) in conformance with 37 C.F.R. §§1.97 and 1.98 for the above-identified patent application. The documents being submitted for consideration by the Examiner are listed on the enclosed Form PTO/SB/08a.

The filing of this IDS shall not be construed as a representation that a search has been made (37 C.F.R. §1.97(g)), nor as an admission that the information submitted herewith is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)) of the subject application.

Pursuant to 37 C.F.R. §1.98(a)(2)(ii), copies of U.S. patents and U.S. patent application publications cited on the accompanying PTO Form PTO/SB/08a are not being submitted. Additionally, pursuant to the Notice in the Official Gazette entitled "Waiver of the Copy Requirement in 37 CFR 1.98 for Cited Pending U.S. Patent Applications" (1287 Off. Gaz. Pat. Office 163 (Oct. 19, 2004)), copies of pending U.S. patent applications cited on the

accompanying PTO Form PTO/SB/08a are also not being submitted. Copies of all other documents cited on the accompanying PTO Form PTO/SB/08a are enclosed herewith.

Applicants also wish to bring to the Examiner's attention the following commonly assigned, co-pending applications:

- (1) U.S. Patent Publication No. US2004/0045044 A1, published on March 4, 2004
- (2) U. S. Patent Application No. 11/008,746, filed on December 9, 2004

Applicants respectfully request that the Examiner consider all of the documents cited on the accompanying PTO Form PTO/SB/08a. After such consideration, the Examiner is respectfully requested to return an initialed copy of the enclosed form PTO/SB/08a to Applicants with the next Office Action on the merits.

This IDS is being filed after the mailing date of the first Office Action on the merits, but before the mailing date of a final action under 37 C.F.R. §1.113. Accordingly, this IDS is accompanied by the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c). A Fee Transmittal form is submitted in duplicate with this information disclosure statement. The Commissioner is hereby authorized to charge any fees for submission of this paper to Deposit Account No. 50-0344.

Any questions regarding this IDS should be directed to undersigned agent for Applicants at (650) 808-3764 (direct).


Respectfully submitted,

THERAVANCE, INC.

Date: May 6, 2005

By: Roberta P. Saxon
Roberta P. Saxon, Ph. D.
Registration No. 43,087

THERAVANCE, INC.
901 Gateway Boulevard
South San Francisco, CA 94080
Tel: (650) 808-6000
Fax: (650) 808-6078



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/691,094
Filing Date	October 22, 2003
First Named Inventor	John H. GRIFFIN
Art Unit	1626
Examiner Name	Janet L. Coppins
Attorney Docket Number	P-144-US2

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	US- 2004/0045044 A1	03-04-2004	Briesewitz et al.	
	A2	US- 11/008,746	Filed 12-09-2004	Briesewitz	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C17	AIELLO et al., "Suppression of retinal neovascularization <i>in vivo</i> by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins", Proc. Natl. Acad. Sci USA, Vol. 92, pp 10457-10461, November 1995	
	C18	DREVS et al., "Effects of PTK787/ZK 222584, a Specific Inhibitor of Fascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model", Cancer Research 60, pp 4819-4824 (September 1, 2000)	
	C19	MENDEL et al., "In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship", Clinical Cancer Research, Vol. 9, pp 327-337 (January 2003)	
	C20	WOOD, "Inhibition of Vascular Endothelial Growth Factor (VEGF) as a Novel Approach for Cancer Therapy", Medicina (Buenos Aires) 60 (Supl. II), pp 41-47 (2000)	
	C21	ZWICK et al., "Receptor tyrosine kinase signalling as a target for cancer intervention strategies", Endocrine-Related Cancer, Vol. 8, pp 161-173 (2001)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.